Trial Number

227-21

Condition

Lung Cancer

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)

This is a Phase III, open-label, randomized, global, multicenter study designed to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab administered to patients with locally-advanced, unresectable Stage III NSCLC who have not progressed following concurrent platinum based of CRT as consolidation therapy.

Provider

Related Clinical Trials

Click on the category you are interested in.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
Are you a current MemorialCare patient?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.